![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 26, 19603-19608, June 30, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
,
,
From the
Centre for Functional Genomics and Human
Disease, Monash Institute of Reproduction and Development, Monash
Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia and
the ¶ Department of Medicine, Box Hill Hospital, Nelson Road,
Box Hill, Victoria 3128, Australia
Received for publication, March 6, 2000, and in revised form, April 6, 2000
| |
ABSTRACT |
|---|
|
|
|---|
In this study, we demonstrate that
methylation-dependent repression of the Pdha-2
core promoter is mediated regionally through a consensus activating
transcription factor/cAMP-responsive element-binding site located
between nucleotides The molecular processes that lead to gene activation at the onset
of spermatogenesis are not well defined. Specifically, those involved
in (i) the activation of early cell-specific gene expression coincident
with the appearance of primary spermatocytes and (ii) the coordination
of the expression of these genes during this period are poorly
understood. What is becoming clearer, however, is the role of
epigenetic influences on gene modulation (1-4). A number of studies
have provided strong correlative evidence that suggests that
demethylation and chromatin reorganization of the germ cell genome are
a prerequisite for gene activation in early spermatocyte
differentiation (5-7). Although DNA hypomethylation, in general,
appears to be a requirement for transcriptional activation, it alone is
not sufficient for the orchestrated activation of spermatocyte-specific
genes. This was initially demonstrated by Ariel et al. (5),
who showed a 10-day delay in transcriptional activation of
Pgk-2 following demethylation of this gene in
prospermatogonia. Similarly, we demonstrated that demethylated
Pdha-2, a gene that encodes the testis-specific E1 Conversely, methylation of Pdha-2 has consistently been
associated with transcriptional inactivity in both spermatogonia and somatic tissues. Although the 187-nucleotide Pdha-2 basal
promoter can direct transcription in a testis- and temporal-specific
manner in vivo, it behaves as a strong constitutive promoter
in vitro (9, 10). In a recent study, we demonstrated that
this constitutive activity in somatic cells can be significantly
reduced following in vitro methylation and showed that an
outcome of methylation is the specific abolition of factor binding to a
consensus ATF1/CRE-binding
site within the Pdha-2 core promoter (9). To gain further
insight into the mechanisms that lead to the activation of
Pdha-2, we sought to look more closely at those processes
that are involved in maintaining transcriptional silencing of this gene
and specifically how methylation mediates this. In this study, we
investigated the relative importance of specific CpG dinucleotides residing within the Pdha-2 core promoter and to what extent
the ATF/CRE-binding site and -binding factor(s) may be involved in this
process. Our data indicate that methylation-dependent
repression is mediated via a CpG dinucleotide within the
ATF/CRE-binding site. The contributions of other CpG dinucleotides are
negligible, although a pair of CpG dinucleotides flanking this binding
site may contribute to a conformational state in a
methylation-independent manner. Furthermore, activation of the promoter
in vivo is dependent upon the binding of an ATF/CRE-binding
factor that appears to be in limiting quantities early in spermatogenesis.
Plasmid Constructions--
The wild-type Pdha-2 core
promoter-CAT construct used in this study has been described elsewhere
(10). Briefly, the core promoter construct contains a fragment of the
Pdha-2 promoter spanning nucleotide sequences from positions
Cell Culture and Transfections--
Mouse NIH 3T3 cells were
grown in Dulbecco's modified Eagle's medium supplemented with 10%
(v/v) fetal calf serum and 100 units/ml penicillin and streptomycin.
Cells were plated at an initial density of 5 × 105
cells/60-mm culture dish and maintained in a 5% CO2
atmosphere at 37 °C. The medium was changed 3 h prior to
transfection. Transfection of plasmid DNA was mediated by DNA/calcium
phosphate coprecipitation (11) using 15 µg of plasmid DNA/plate. Six
hours following transfection, the medium was removed, and cells washed
twice with serum-free medium and then incubated with complete medium
until ready for harvesting 48 h later.
Methylation of Pdha-2 Core Promoter by SssI
Methylase--
In vitro methylation of promoter constructs
(10 µg) was performed following an overnight incubation at 37 °C
in the presence of 1 unit of SssI methylase (New England Biolabs Inc.)
and 160 µM S-adenosylmethionine.
Generation of Transgenic Mice--
The promoter-CAT constructs
were linearized and prepared for pronuclear microinjection using
standard procedures (12). Fertilized eggs were obtained from
superovulated 6-week-old F1(CBA × C57/6J) female mice.
CAT Assays, EMSA, DNase I Footprinting, and Nuclear Extract
Preparation--
CAT assays and the preparation of cell extracts were
performed as described previously (11) using
[14C]chloramphenicol. Activity was determined by
measuring acetylated and unreacted [14C]chloramphenicol
products following ascending thin-layer chromatography and
visualization using a Fujix BAS 1000 image analyzer. Electrophoretic mobility shift and DNase I footprinting assays were performed using
nuclear extracts prepared from mouse testis and brain as described by
Iannello et al. (10). In experiments in which antibodies were used in gel shift assays, antibodies were preincubated with nuclear extracts 10 min prior to the addition of the radiolabeled double-stranded ATF/CRE-binding oligonucleotide. Double-stranded oligonucleotides used in this study that spanned the Pdha-2
ATF/CRE and hypersensitive sites consisted of the wild-type pQ
oligonucleotide (5'-CTTGCTGACGTAG GCAACGCG-3'), CpG Methylation Abrogates Pdha-2 Promoter Activity Specifically
through an ATF/CRE cis-Element--
In a previous study, we had
established an in vivo correlation between transcriptional
activation and demethylation of 5-methylcytosine nucleotides along the
length of the Pdha-2 core promoter (9). In the same study,
we demonstrated that in vitro methylation of this promoter
by SssI methylase significantly reduced its ability to direct reporter
gene expression in NIH 3T3 cells. A particularly interesting
observation resulting from this earlier work was that CpG methylation
specifically inhibited nuclear factor binding to an ATF/CRE-binding
site within the promoter. Coinciding with a loss in factor binding was
a notable loss of a DNase I-hypersensitive site residing between the
ATF/CRE and MEP2-binding sites. Both the ATF/CRE site and DNase
I-hypersensitive region contain CpG dinucleotides (Fig.
2). To ascertain the extent to which
these changes contribute to the observed
methylation-dependent silencing of promoter activity, we
generated cassettes in which specific CpG dinucleotides within the
Pdha-2 core promoter were mutated (Fig. 1), and the
subsequent effects of in vitro CpG methylation were assessed
by CAT reporter assays following transient transfection into NIH 3T3
cells (Table I).
Consistent with our previous studies, the wild-type Pdha-2
promoter (pQCAT) showed a significant reduction (68%) in activity following SssI methylase treatment compared with its untreated control
(Fig. 3A). As a first step
toward examining the relative contribution of specific CpG
dinucleotides to this reduction, we generated a promoter construct
(pQ
Additional evidence that methylation-dependent silencing of
the Pdha-2 promoter may be mediated predominantly via the
ATF/CRE site is derived from the analysis of Pdha-2 promoter
cassettes harboring CpG mutations flanking the functional ATF/CRE site
(Fig. 1). In vitro methylation of pQ1.5CAT, in which the CpG
dinucleotide pair in the hypersensitive site was substituted for GATC,
reduced promoter activity by 65% compared with its untreated control
(Fig. 3B). The GATC substitution has no direct effect on
transcription factor binding to the flanking ATF/CRE site as determined
by EMSA (Fig. 4), and the CpG dinucleotide within the ATF/CRE
cis-element still remains subject to methylation.
Importantly, the percentage reduction in promoter activity following
SssI methylase treatment of pQ1.5CAT is similar to that observed
following methylation of the wild-type promoter and following
perturbation of the ATF/CRE site in pQ A CpG Dinucleotide Pair Confers Functional Constraint on the Pdha-2
Promoter in a Methylation-independent Manner--
An analysis of total
CAT activities directed by wild-type and CpG mutant promoters (Fig.
5) led to an unexpected finding. Relative
to cells transfected with pQCAT (Fig. 5, bar a), those transfected with pQ1.5CAT (bar b) showed 68% higher levels
of CAT activity. Although modest, this elevated level of expression was
consistent. A possible explanation for this result may be that the CpG
dinucleotide pair residing within the hypersensitive site confers some
structural or conformational constraint on the promoter. Consistent
with this hypothesis is the observation that promoter constructs
harboring the GATC substitution (pQ1.5CAT and pQ2.5CAT) retain higher
levels of residual or basal activities compared with their respective
controls following either in vitro methylation or
perturbation of the ATF/CRE-binding site. As shown in Fig. 5, the
residual or basal level of activity directed by the promoter cassette
in pQ2.5CAT (Fig. 5, bar d) is ~2-fold higher than its
respective control, pQ ATF/CRE Binding Is Essential for Pdha-2 Promoter Activity in
Vivo--
Given that our data implicate the ATF/CRE-binding site as
having a central role in vitro in the methylation-mediated
repression of the Pdha-2 core promoter, we were interested
in determining the functional relevance of this site in
vivo. We generated a number of transgenic mouse lines harboring
the wild-type Pdha-2 promoter-CAT, pQ1.5CAT, or pQ2.5CAT
cassette and analyzed the level of CAT activity driven by each promoter
in testis. The results presented in Fig.
6 show that the Pdha-2
promoter in mice harboring both the wild-type and pQ1.5CAT cassettes
can actively drive the expression of the CAT reporter gene in testis.
Conversely, no detectable levels of CAT activity in testes from mice
harboring pQ2.5CAT cassette could be demonstrated. Our results
establish that the ATF/CRE site is necessary for promoter activation
and further support the notion that in vivo targeting of
this site via a methylation-mediated mechanism is sufficient to
completely inactivate promoter activity.
ATF/CRE Binding Is Limiting Prior to the Onset of
Spermatogenesis--
An early event in spermatogenesis is the
differentiation of type B spermatogonia into primary spermatocytes. The
appearance of spermatocytes correlates with the induction of a number
of early spermatocyte-specific genes, including Pdha-2. It
has already been demonstrated that the Pdha-2 promoter is in
a hypomethylated state and transcriptionally active in spermatocytes
(9). However, in the same study, we demonstrated that hypomethylation
of the Pdha-2 promoter is initially detectable in
spermatogonia, in which this gene is inactive. It has been postulated
that during the spermatogonium-spermatocyte transition, a number of
events occur that may potentiate transcriptional activity, including
the recruitment of transcription factors. To gain some insights as to
what mechanism(s) maintain silencing of Pdha-2 in
spermatogonia, we examined the pattern of transcription factor binding
on the Pdha-2 promoter during sexual maturation in mice.
This was achieved by performing DNase I footprinting assays using
testis nuclear extracts prepared from mice at various stages of sexual
maturation. The results shown in Fig. 7
indicate that in testes of 8-day postnatal mice, the transcription
factor Sp1 was present in sufficient quantities in our extracts to
protect its cognate binding site from DNase I nicking. By day 15, protection was also apparent over the YY1- and MEP2-binding sites. By
day 20, all known transcription factor-binding sites residing within
the Pdha-2 core promoter were protected. At this stage,
primary spermatocytes are abundant, and Pdha-2 transcripts
are easily detectable by Northern blot analysis (8). The lack of
protection of the ATF/CRE-binding site in extracts from 15-day-old
mouse testis is, however, not indicative of an absence of factors that
bind to this site. Indeed, earlier EMSA studies (10) clearly
demonstrated that protein-DNA complexes involving the ATF/CRE site were
formed in nuclear extracts prepared from testes of mice as early as
postnatal day 12. These data more likely suggest that factors that
recognize the ATF/CRE-binding site are present, but less abundant
relative to other nuclear factors during the early stages of
spermatogenesis.
The identity of the specific factor that recognizes the ATF/CRE site
within the Pdha-2 promoter has not yet been determined. EMSA
analysis using adult mouse testis and brain nuclear extracts showed two
distinct patterns (Fig. 8). Brain
extracts were used in these experiments for comparative analysis
between two tissue preparations. NIH 3T3 nuclear extracts showed
identical profiles compared with brain nuclear extracts (data not
shown). Factors in brain extracts formed a single complex with
double-stranded oligonucleotides containing the Pdha-2
ATF/CRE-binding site. This complex could be supershifted by antibodies
raised against CREB and was predominantly abolished by antibodies
raised against CREM. However, in testis, multiple complexes were
observed, the majority of which remained unaltered by the presence of
either the anti-CREB or anti-CREM antibodies. Furthermore, antibodies
raised against either the ATF-1 or ATF-2 transcription factor also
failed to alter the pattern. These data suggest that a member of the
ATF/CRE family other than those tested here is actively involved in
Pdha-2 activation during the meiotic prophase stage of
spermatogenesis.
The objective of this study was to gain an understanding of the
mechanisms responsible for the transcriptional silencing of Pdha-2. During spermatogenesis, Pdha-2 expression
coincides with the appearance of early primary spermatocytes (8, 14),
whereas in the spermatocyte precursor cells (spermatogonia),
transcriptional activity is silenced. Similarly, no detectable levels
of Pdha-2 transcription are observed in somatic tissue. In
each case, methylation of the Pdha-2 promoter has been
demonstrated to functionally correlate with the absence of activity
(9). Interestingly, prior to transcriptional activation, the
Pdha-2 promoter undergoes demethylation in a subpopulation of spermatogonia, but remains inactive until these cells undergo differentiation into primary spermatocytes. It has been proposed that
during this spermatogonium-spermatocyte transition, transcriptional activation is preceded by a number of events that subsequently lead to
activation. This period of "potentiation" (6) is believed to
involve epigenetic modifications and changes in transcription factor constituency.
Before we can gain insights into this process, we sought to better
understand the molecular mechanisms by which
methylation-dependent inactivation of Pdha-2 is
mediated. The TATA-less and CAAT-less Pdha-2 core promoter
is composed of ~187 base pairs and contains four major transcription
factor-binding sites, three of which are the Sp1, ATF/CRE, and YY1
sites. Although the Pdha-2 promoter is not a CpG
island-containing promoter, several CpG dinucleotides reside within or
in close proximity to these transcription factor-binding sites.
Therefore, our initial investigations were directed at determining the
relative contribution of some of these specific CpG dinucleotides to
the modulation of Pdha-2 promoter activity. Our analysis
established that the CpG dinucleotide located within the
ATF/CRE-binding element is primarily responsible for mediating methylation-dependent silencing of this promoter in
vitro. This conclusion was further strengthened by our observation
that this site is critical for functional activation of the promoter
in vivo. In contrast, methylation of CpG dinucleotides
located within or close to the Sp1- and YY1-binding sites does not
appear to contribute to the silencing of the Pdha-2
promoter, although our data do not exclude a possible contribution that
may be masked as a result of a reduced basal activity level following
the ablation of ATF/CRE binding. Nevertheless, the data are consistent
with previous studies that have demonstrated both transcription factor sensitivity and insensitivity to CpG methylation on several binding sites (15, 16).
The delay in transcriptional activation of hypomethylated genes during
the spermatogonium-spermatocyte transition period was originally
observed with Pgk-2 by Ariel et al. (5). Since
Pdha-2 behaves in a similar manner, this suggests that
hypomethylation is an early component in the potentiation process and
that it precedes other events such as transcription factor recruitment and/or chromatin reorganization. Given the importance of the
ATF/CRE-binding site for Pdha-2 activity, we performed DNase
I footprinting assays to determine whether availability of the
factor(s) that bind to this site could offer an explanation for the
latent activation of the promoter following hypomethylation. Our data
clearly show that the factor(s) binding to this site is limiting in
nuclear extracts prepared from testis coincident with early stages of spermatogenesis. Similar experiments using extracts prepared from purified spermatogonia and spermatocytes will be required to determine unequivocally whether our data correlate with a spermatocyte-specific appearance of this factor. Nevertheless, our results strengthen the
notion that transcription factor recruitment/availability following
hypomethylation may, in part, account for the delay in the activation
of the Pdha-2 promoter and are further evidence implicating
the ATF/CRE site as central for promoter functionality.
The specific factor that recognizes the ATF/CRE site within the
Pdha-2 promoter has not yet been determined. EMSA analysis using adult mouse testis and brain nuclear extracts showed two distinct
patterns. A single complex is formed with brain extracts that can be
supershifted by antibodies raised against CREB and that is
predominantly abolished by antibodies raised against CREM. However, in
testis, multiple complexes are observed, the majority of which remain
unaltered by the presence of either the anti-CREB or anti-CREM
antibodies. Furthermore, antibodies raised against either the ATF-1 or
ATF-2 transcription factor also fail to alter the pattern. CREM may be
excluded as a candidate since CREM activator protein is expressed only
in haploid germ cells (17). The role of CREB in spermatogenesis is
unclear since knockout mice null for CREB show no spermatogenic defects
(18). However, given that (i) the integrity of the pyruvate
dehydrogenase complex is central for mitochondrial function and (ii)
the factor binding to the ATF/CRE site in the Pdha-2
promoter is essential for activity, the absence of any apparent
deleterious spermatogenic phenotype with the CREB-null mice would also
suggest that CREB is an unlikely candidate for the factor that binds to
the Pdha-2 promoter during the early stages of
spermatogenesis. Identification of this factor may prove to be
significant in that it may provide us with some insights into early
spermatogenic differentiation akin to the role CREM plays in spermiogenesis.
An interesting observation from our analysis of the Pdha-2
promoter was the elevation in promoter activity following mutagenesis of a pair of CpG dinucleotides flanking the ATF/CRE-binding site. Although the elevation is modest, it needs to be viewed in the context
of a basal promoter-driven activity. It would be interesting to
determine if a higher level of activation could be attained if these
mutations were present in vivo. Experimentally, this would
have to be performed in the context of the highly active full-length
promoter since the activity of the core promoter alone in
vivo is particularly low (9), making differences between pQCAT and
pQ1.5CAT difficult to detect. Indeed, transgenic mouse lines harboring
either pQCAT or pQ1.5CAT show no significant differences when comparing
CAT activities driven by the transgenic promoters. Random integration,
copy number, relatively low basal activities, and the limited number of
transgenic lines for each construct (n = 5) make an
accurate comparison difficult. Our in vitro data are,
however, not entirely surprising. Crystal engineering experiments have
revealed a specific role for CpG sequences in DNA-DNA recognition, where they act as anchoring points for DNA self-fitting (19). As such,
it has been suggested that CpG dinucleotides may participate in the
formation of higher order DNA structures. Therefore, perturbations in
gene expression through CpG mutations may occur in at least one of
three ways: first, through the disruption of transcription factor-binding sites, thereby inactivating or reducing transcriptional activity; second, by rendering local regions along regulatory DNA
sequences incapable of being methylated, thereby maintaining active
transcription; and finally, a third process whereby mutations of
specific GpG dinucleotides, which do not play a role in regional methylation-mediated modulation, affect the three-dimensional organization of DNA segments and subsequently gene expression. In our
case, mutations of the CpG dinucleotide pair in the Pdha-2 core promoter resulted in an elevated level of transcriptional activity. The observed increased activity is not likely to have occurred as a result of changes in protein-DNA interactions since footprinting studies demonstrated no observable differences in protection of transcription factor-binding sites when comparing pQ1.5CAT and wild-type
pQCAT.2 One mechanism by
which mutations in the CpG dinucleotide pair flanking the ATF
site may modulate transcriptional expression is through a change in DNA
conformation such that it facilitates greater stability in
protein-protein interactions. This would be consistent with our
in vitro transfection data and footprinting analysis. Given
that CpG dinucleotides are underrepresented in higher eukaryotic
genomes due to the high mutability of methylated cytosine and that this
is thought to contribute to genetic disease and cancer (20), our data
may point to another model of transcriptional deregulation that may
explain some of these disorders.
In conclusion, to better understand the mechanisms that orchestrate the
activation of testis-specific genes in early spermatogenic cells, we
sought to investigate the processes that precede activation. Using the
Pdha-2 core promoter as a model of study, we conclude from
our data that methylation-dependent repression acts via a local rather than global mechanism and that this is mediated through the ATF/CRE-binding site. Availability of the factor(s) that bind to
this site may also add another level of modulatory complexity. Since
the ATF/CRE-binding site is widespread, ablation of factor binding to
this site through methylation may be a common mechanism by which
silencing of early spermatogenic genes can be achieved.
54 and
62 upstream of the major transcriptional
start site. Targeting of the CpG dinucleotide within this
cis-element significantly disrupts the ability of this
basal promoter to activate gene expression in vitro and
completely abolishes promoter activity in vivo. DNase I
footprinting experiments indicated that availability of the nuclear
factor(s) binding this element is limiting in sexually immature mouse
testis, and as such, these factors may play an important role in the
coordinate activation of early spermatogenic gene expression.
Interestingly, CpG dinucleotides associated with the hypersensitive
region flanking the activating transcription factor/cAMP-responsive
element-binding site appear to confer some conformational
structure on the promoter since mutations at these specific CpG
dinucleotides result in elevated basal levels of transcription. This
raises the possibility of a potential bifunctional role for CpG
dinucleotides in either methylation-dependent or -independent
processes. Our data support the notion that hypomethylation and
transcription factor recruitment are necessary events that
precede gene activation at the early stages of spermatogenesis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
subunit of the pyruvate dehydrogenase complex (8), remains
transcriptionally silent in a subpopulation of spermatogonia, but is
active in pachytene spermatocytes (9).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
187 to +22 relative to the transcriptional start site. This promoter
cassette was cloned into the CAT reporter-containing vector pCAT-Basic
(Promega). In this study, we have designated this construct as pQCAT.
To generate various mutant promoter constructs, we used, as a
polymerase chain reaction strategy, primers containing appropriate
nucleotide substitutions and the core promoter as template. These
promoter cassettes were subsequently cloned into pCAT-Basic and
confirmed by sequencing. To generate pQ
CRECAT, we used the above
strategy to substitute the CpG dinucleotide at positions
56 and
55
(within the ATF/CRE-binding site) with CpA (Fig.
1). pQ1.5CAT was generated by mutating
the CpG dinucleotide pair at positions
47 to
44 from CGCG to GATC.
Finally, to generate pQ2.5CAT, we used the pQ
CRE promoter as
template and sequence modified primers such that the final construct
contains the CpA substitution within the ATF/CRE-binding site as well
as the GATC substitution at nucleotides
47 to
44.

View larger version (16K):
[in a new window]
Fig. 1.
Diagrammatic representation of the nucleotide
substitutions generated in the various Pdha-2 core
promoter constructs. The Pdha-2 ATF/CRE-binding site is
underlined. The CpG dinucleotides at both the
ATF/CRE-binding and flanking hypersensitive sites in the wild-type
promoter along with the various permutations in the mutant promoters
are shown in uppercase letters.
CRE
(5'-CTTGCTGACATAG GCAACGCG-3'), 1.5 (5'-CTTGCTGAC GTAGGCAAGATC-3'), and
2.5 (5'-CTTGCTGA CATAGGCAAGATC-3'). Pdha-2 core promoter
probes used for DNase I footprinting analysis was generated by
polymerase chain reaction as described by Iannello (13).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (16K):
[in a new window]
Fig. 2.
Nucleotide sequence of the Pdha-2
core promoter spanning positions
187 to +22.
Transcription factor-binding sites identified by DNase I footprinting
assays (13) are indicated, and the nucleotide sequence is shown in
boldface lowercase letters. CpG dinucleotides are shown as
boldface uppercase letters and are indicated by
asterisks. bp, base pairs.
Effect of in vitro promoter methylation on CAT activities in NIH 3T3
cells transiently transfected with wild-type and mutant Pdha-2 core
promoter-CAT constructs
CRECAT) containing a single nucleotide substitution (CpG to CpA)
within the ATF/CRE-binding site. A consequence of this substitution is
that nuclear factor binding to the ATF/CRE cis-element is
ablated as demonstrated by EMSA analysis (Fig.
4). In this respect, the outcome of this mutation is similar to that observed following methylation of the
wild-type promoter, in which binding to the ATF/CRE-binding site is
abolished. Results from transient transfection assays indicated that
the CpA substitution alone was sufficient to reduce promoter activity
by 60% (Fig. 3A). Interestingly, there was no statistical
difference between this reduction and that observed following the
in vitro methylation of the wild-type promoter, suggesting
that the ATF/CRE element may be central to the
methylation-dependent silencing of the Pdha-2
gene. Supporting this notion are the results of experiments showing the
effect of in vitro methylation on pQ
CRECAT reporter
activity. In these studies, only a further 13% reduction in promoter
activity was observed following SssI methylase treatment compared with
the untreated construct, suggesting that the involvement of the
remaining CpG dinucleotides in this mechanism may be marginal.

View larger version (15K):
[in a new window]
Fig. 3.
Histogram showing the relative mean CAT
activities of the wild-type and mutant Pdha-2 promoters.
A, effects of SssI methylase treatment on the wild-type
(pQCAT) and pQ
CRECAT constructs. Meth indicates
methylated. Values were taken from Table I, and CAT activity is
expressed relative to pQCAT. B, effects of SssI methylase
treatment on pQ1.5CAT and pQ2.5CAT constructs. Values were taken from
Table I, and CAT activity is expressed relative to pQ1.5CAT.

View larger version (37K):
[in a new window]
Fig. 4.
EMSA analysis showing the effects of
nucleotide substitutions within the ATF/CRE and flanking hypersensitive
sites on transcription factor binding. Radiolabeled
double-stranded oligonucleotides (2 ng) containing both these regions
were incubated with 10 µg of NIH 3T3 nuclear extracts. The wild-type
Pdha-2 ATF/CRE and hypersensitive sites are represented by
the double-stranded oligonucleotide designated pQ. The double-stranded
oligonucleotide
CRE is identical to pQ with the exception of a CpA
substitution of CpG within the ATF/CRE-binding site. Nucleotide
substitutions in the hypersensitive site but containing a functional
ATF/CRE site as found in the promoter construct pQ1.5CAT are
represented in the double-stranded oligonucleotide 1.5. The
oligonucleotide designated 2.5 is identical to 1.5, except that it also
contains the CpA substitution within the ATF/CRE-binding site. The
closed arrow represents unbound labeled double-stranded
oligonucleotide. The open arrow represents complexes bound
to the labeled double-stranded oligonucleotide.
CRECAT. Furthermore, following
the introduction of an additional CpG-to-CpA substitution within the
ATF/CRE site to generate the mutant construct pQ2.5CAT, SssI methylase
treatment did not confer any further inhibitory effect on pQ2.5CAT
relative to its untreated control (Fig. 3B), strongly
implying that repression is being mediated through the ATF/CRE-binding
site. Our data clearly suggest that a critical target of in
vitro CpG methylation on the Pdha-2 core promoter
resides with the CpG dinucleotide within the ATF/CRE site and that
repression consequently results from a loss of nuclear factor binding
to this cis-element. The contribution of other CpG
dinucleotides along the length of the promoter in this process appears
to be negligible.
CRECAT (bar c). SssI methylase treatment of pQ1.5CAT (Fig. 5, bar f) and pQ2.5CAT
(bar h) had no effect on their respective residual basal
levels of activity compared with their appropriate methylated controls
(bars e and g). Our results suggest that the CpG
dinucleotide pair flanking the ATF/CRE-binding site may confer some
conformational constraint on the Pdha-2 promoter and that
this function is distinct and independent of the methylation-induced
repression of promoter activity mediated through the ATF/CRE-binding
site.

View larger version (10K):
[in a new window]
Fig. 5.
Histogram showing the percentage
Pdha-2 promoter-driven CAT activities assayed in NIH
3T3 cells. Bar a, pQCAT; bar b, pQ1.5CAT;
bar c, pQ
CRECAT; bar d, pQ2.5CAT; bar
e, SssI methylase-treated pQCAT; bar f, SssI
methylase-treated pQ1.5CAT; bar g, SssI methylase-treated
pQ
CRECAT; bar h, SssI methylase-treated pQ2.5CAT. Values
were taken from Table I, and all CAT activities are expressed relative
to pQCAT. The asterisks signify statistical significance
using Student's t test, p < 0.05.

View larger version (32K):
[in a new window]
Fig. 6.
Representative CAT assay performed on mouse
testes obtained from transgenic lines harboring the wild-type promoter
(pQCAT; A), pQ1.5CAT (B), or pQ2.5CAT
(C). Mouse lines for each of the transgenic
constructs are numbered individually. +, CAT-positive control;
,
nontransgenic negative control.

View larger version (54K):
[in a new window]
Fig. 7.
DNase I footprinting assay performed on the
Pdha-2 core promoter using testis nuclear extracts
prepared from 8-, 15-, and 20-day-old mice. The first
lane represents the polymerase chain reaction-generated
Pdha-2 probe DNase I-treated in the absence of nuclear
extract. d, days.

View larger version (44K):
[in a new window]
Fig. 8.
EMSA analysis of the Pdha-2
ATF/CRE-binding site. A radiolabeled double-stranded
oligonucleotide containing the Pdha-2 ATF/CRE-binding site
was incubated with either adult mouse testis nuclear extract
(upper panel) or adult mouse brain nuclear extract
(lower panel) and then subjected to an electrophoretic
mobility shift assay. When antibodies (Ab) to various
CREM/CREB/ATF family members were used in mobility shift assays, these
were preincubated with the extracts prior to the addition of the
end-labeled probe. In each panel, self refers to competition
with the same unlabeled double-stranded oligonucleotide. 71B
refers to competition with an unrelated unlabeled double-stranded
oligonucleotide. The open arrow indicates shifted complexes.
The closed arrow indicates supershifted complexes resulting
from complex-antibody interactions.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 61-3-9594-7207; Fax: 61-3-9594-7211; E-mail: Rocco.Iannello@med.monash. edu.au.
Published, JBC Papers in Press, April 13, 2000, DOI 10.1074/jbc.M001867200
2 R. C. Iannello, J. A. Gould, J. C. Young, and Kola, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ATF, activating transcription factor; CRE, cAMP-responsive element; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay; CREB, cAMP-responsive element-binding protein; CREM, cAMP-responsive element modulator.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Eden, S., Hashimshony, T., Keshet, I., and Cedar, H. (1998) Nature 394, 842 |
| 2. | Jones, P. L., Jan Veenstra, G. C., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., and Wolffe, A. P. (1998) Nat. Genet. 19, 187-191 |
| 3. | Kass, S. U., Pruss, D., and Wolffe, A. P. (1997) Trends Genet. 13, 444-449 |
| 4. | Siegfried, Z., and Ceder, H. (1997) Curr. Biol. 7, R305-R307 |
| 5. | Ariel, M., Ceder, H., and McCarrey, J. (1994) Nat. Genet. 7, 59-63 |
| 6. | Kramer, J. A., McCarrey, J. R., Djakiew, D., and Krawetz, S. A. (1998) Development 125, 4749-4755 |
| 7. | Zhang, P. L., Stroud, J. C., Walker, C. A., Adrian, G. S., and McCarrey, J. R. (1998) Biol. Reprod. 59, 284-292 |
| 8. | Iannello, R. C., and Dahl, H. H.-M. (1992) Biol. Reprod. 47, 48-58 |
| 9. | Iannello, R. C., Young, J., Summarsono, S., Gould, J., Tymms, M., Dahl, H. H.-M., Hedger, M., and Kola, I. (1997) Mol. Cell. Biol. 17, 612-619 |
| 10. | Iannello, R. C., Kola, I., and Dahl, H. H.-M. (1993) J. Biol. Chem. 268, 22581-22590 |
| 11. | Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051 |
| 12. | Hogan, B., Constantini, F., and Lacey, E. (1986) Manipulating the Mouse Embryo , Cold Spring Harbor Press, Cold Spring Harbor, NY |
| 13. | Iannello, R. C. (1995) in Methods in Molecular Biology: In Vitro Transcription and Translation Protocols (Tymms, M. J., ed), Vol. 37 , pp. 379-391, Humana Press Inc., Totowa, NJ |
| 14. | Takakubu, F., and Dahl, H. H.-M. (1992) Exp. Cell Res. 199, 39-49 |
| 15. | Iguchi-Ariga, S. M. M., and Schaffner, W. (1989) Genes Dev. 3, 612-619 |
| 16. | Tate, P. H., and Bird, A. (1993) Curr. Opin. Genet. Dev. 3, 226-231 |
| 17. | Steger, K. (1999) Anat. Embryol. 199, 471-487 |
| 18. | Hummler, E., Cole, T. J., Blendy, J. A., Ganss, R., Aguzzi, A., Schmid, W., Beermann, F., and Schutz, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5647-5651 |
| 19. | Mayer-Jung, C., Moras, D., and Timsit, Y. (1997) J. Mol. Biol. 270, 328-335 |
| 20. | Jackson-Grusby, L., and Jaenisch, R. (1996) Semin. Cancer Biol. 7, 261-268 |
This article has been cited by other articles:
![]() |
K. Tokuhiro, Y. Miyagawa, S. Yamada, M. Hirose, H. Ohta, Y. Nishimune, and H. Tanaka The 193-Base Pair Gsg2 (Haspin) Promoter Region Regulates Germ Cell-Specific Expression Bidirectionally and Synchronously Biol Reprod, March 1, 2007; 76(3): 407 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rodic, M. Oka, T. Hamazaki, M. R. Murawski, M. Jorgensen, D. M. Maatouk, J. L. Resnick, E. Li, and N. Terada DNA Methylation Is Required for Silencing of Ant4, an Adenine Nucleotide Translocase Selectively Expressed in Mouse Embryonic Stem Cells and Germ Cells Stem Cells, September 1, 2005; 23(9): 1314 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, D. T. Odom, S.-H. Koo, M. D. Conkright, G. Canettieri, J. Best, H. Chen, R. Jenner, E. Herbolsheimer, E. Jacobsen, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues PNAS, March 22, 2005; 102(12): 4459 - 4464. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hisano, H. Ohta, Y. Nishimune, and M. Nozaki Methylation of CpG dinucleotides in the open reading frame of a testicular germ cell-specific intronless gene, Tact1/Actl7b, represses its expression in somatic cells Nucleic Acids Res., August 15, 2003; 31(16): 4797 - 4804. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fujita, R. Fujii, S. Aratani, T. Amano, A. Fukamizu, and T. Nakajima Antithetic Effects of MBD2a on Gene Regulation Mol. Cell. Biol., April 15, 2003; 23(8): 2645 - 2657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Weitzel, N. B. Shiryaeva, R. Middendorff, M. Balvers, C. Radtke, R. Ivell, and H. J. Seitz Testis-Specific Expression of Rat Mitochondrial Glycerol-3-Phosphate Dehydrogenase in Haploid Male Germ Cells Biol Reprod, February 1, 2003; 68(2): 699 - 707. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Xie, S. Han, M. Khan, and J. DeJong Regulation of ALF Gene Expression in Somatic and Male Germ Line Tissues Involves Partial and Site-specific Patterns of Methylation J. Biol. Chem., May 10, 2002; 277(20): 17765 - 17774. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Schmitt, D. S. Millar, J. S. Pedersen, S. L. Clark, D. J. Venter, M. Frydenberg, P. L. Molloy, and G. P. Risbridger Hypermethylation of the Inhibin {alpha}-Subunit Gene in Prostate Carcinoma Mol. Endocrinol., February 1, 2002; 16(2): 213 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Kroft, P. Jethanandani, D. J. McLean, and E. Goldberg Methylation of CpG Dinucleotides Alters Binding and Silences Testis-Specific Transcription Directed by the Mouse Lactate Dehydrogenase C Promoter Biol Reprod, November 1, 2001; 65(5): 1522 - 1527. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Griswold and J.-S. Kim Site-Specific Methylation of the Promoter Alters Deoxyribonucleic Acid-Protein Interactions and Prevents Follicle-Stimulating Hormone Receptor Gene Transcription Biol Reprod, February 1, 2001; 64(2): 602 - 610. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME |